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THE new Immunosuppressant .• FK 506. was first used in humans on a compassionate basis. for patients 
suffering from mtractable rejection or disabling side effects 
of cyclosporine (eyAI therapy.I-) This repon is a brief 
overview of a much larger experience·with a longer follow-
up. presented in detail elsewhere.4 
PATIENTS AND METHODS 
Patient Selection 
The clinicopathologic profile of all liver allograft reCIpients who 
were convened from CyA-steroid to FK S06 therapy during the 
penod of March I. 1989 until December IS. 1989 was reviewed. 
NiDety-slx of \36 patients Identified were Included in this study 
based on the follOWing cntena: ( I) biochemical graft dvsfunctlon. 
as defined bv elevated liver function tests (>S()Iif over normal 
valuesl In the absence of mechanical causes: and (2) availability of 
a liver biOpsy Within 7 days before the SWllch. with at least one 
follow-up biopsy afterward. 
All patients were followed until September 9. 1990. graft failure. 
or death. which ever came first. The results of liver function tests 
were recorded. 30. 60. 90. and 180 days after conversion. 
PathologiC Studies 
The diagnOSIs of acute and chrOniC liver allograft rejection was 
based on prevIOusly published cntena.'" 
RESULTS 
The results of conversion to FK 506 were stratified accord-
ing to (he reason for conversion. based on the clinico-
pathologiC profile of each patient prior to the switch. The 
results are summarized in Table I. As can be seen. the 
majority of patients whose graft dysfunction was attribut-
able to acute or the early stages of chronic rejection. while 
under conventional therapy, responded favorably to the 
conversion to FK 506. All but two of the 18 patients 
switched for acute rejection had received additional ste-
roid (n = 12) and/or OKT3 (n = 7) before conversion. 
Nonrejection causes of graft dysfunction were mostly 
unaffected pathologically by FK 506. except for acute or 
chronic active hepatitis. which proved to be a poor indi-
cation for conversion. Improvement of biochemical pa-
rameters of liver injury was more common than pathologic 
improvement in all categories. The discrepancy may have 
been due to discordance between the date of last biopsy 
and liver function test monitoring. 
Transient FK 506 nephrotoxicity was often observed at 
the time of drug switch and was severe in some patients. 
although none required dialysis. However. for all patients 
taken as a group. there was no significant change m serum 
creatinine values 180 days after conversion to FK 506 
(mean serum creatinine pre·FK 506 = 1.8 :: 0.9mgldL. 
post-FK S06 = 1.9 :: 0.9 mgldL: P > .05). 
DISCUSSION 
The results of this analysis suggest that FK 506 is a more 
potent immunosuppressant than other current agents. 
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However. it may be that conversion to a new immunosup-
pressant after the development of rejection can effectively 
control a clone of lymphocytes that was selected prior to 
the switch. because of its resistance to the onginal regi-
men.' 
Regardless. the data generated from this study cannot be 
used for a comparison of FK 506 with continuation of 
conventional therapy. since the latter option was consid-
ered inhumane. A more direct comparison. as is now being 
conducted in the randomized European and American 
trials. should yield more definitive answers. Also. a com-
parison and quantification of the side effects will be 
achieved. The results reported herein for rescue patients 
place FK 506 in a favorable light. However. continued 
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follow-up of these and other patients for potential chronic 
toxicity will place FK 506 in its proper perspective in the 
immunosuppressi ve arsenal. 
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